Loading…

KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH‐DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

Saved in:

Bibliographic Details
Published in:	Hematological oncology 2017-06, Vol.35 (S2), p.94-95
Main Authors:	Ferrero, S., Rossi, D., Bruscaggin, A., Evangelista, A., Di Rocco, A., Spina, V., Stefoni, V., Ghione, P., Barbero, D., Monitillo, L., Gomes Da Silva, M., Santoro, A., Molinari, A., Ferreri, A., Piccin, A., Cortelazzo, S., Ladetto, M., Gaidano, G.
Format:	Article
Language:	English
Subjects:	Lymphoma Mantle Mantle cell lymphoma Mutation p53 Protein Therapy
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!